Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Mohr

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Clinical Pharmacokinetics|May 13, 2025
An Adult Population Pharmacokinetic Model to Simulate Subcutaneous Administration of a Fixed Dose of Furosemide in Adolescents with Heart Failure and Volume OverloadChristoph P Hornik, Henry P Foote, Eric Kendig, et al.
Antimicrobial Agents and Chemotherapy|March 2, 2016
Fluoroquinolone and Third-Generation-Cephalosporin Resistance among Hospitalized Patients with Urinary Tract Infections Due to Escherichia coli: Do Rates Vary by Hospital Characteristics and Geographic Region?Monique R Bidell, Melissa Palchak, John Mohr, et al.
Pharmacotherapy|May 2, 2008
Current options in antifungal pharmacotherapyJohn Mohr, Melissa Johnson, Travis Cooper, et al.
International Journal of Antimicrobial Agents|February 12, 2013
Safety of daptomycin in patients completing more than 14 days of therapy: results from the Cubicin® Outcomes Registry and experienceShruta Rege, John Mohr, Kenneth C Lamp, et al.
Emerging Infectious Diseases|June 21, 2005
Community-associated methicillin-resistant Staphylococcus aureus in pediatric patientsTheresa J Ochoa, John Mohr, Audrey Wanger, et al.
BMC Infectious Diseases|March 1, 2017
Effect of prior receipt of antibiotics on the pathogen distribution and antibiotic resistance profile of key Gram-negative pathogens among patients with hospital-onset urinary tract infectionsMonique R Bidell, Melissa Palchak Opraseuth, Min Yoon, et al.
Journal of Clinical Microbiology|March 31, 2012
Correlation of clinical outcomes with β-glucan levels in patients with invasive candidiasisCharles R Sims, Siraya Jaijakul, John Mohr, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Clinical Pharmacokinetics|May 13, 2025
An Adult Population Pharmacokinetic Model to Simulate Subcutaneous Administration of a Fixed Dose of Furosemide in Adolescents with Heart Failure and Volume OverloadChristoph P Hornik, Henry P Foote, Eric Kendig, et al.
Antimicrobial Agents and Chemotherapy|March 2, 2016
Fluoroquinolone and Third-Generation-Cephalosporin Resistance among Hospitalized Patients with Urinary Tract Infections Due to Escherichia coli: Do Rates Vary by Hospital Characteristics and Geographic Region?Monique R Bidell, Melissa Palchak, John Mohr, et al.
Pharmacotherapy|May 2, 2008
Current options in antifungal pharmacotherapyJohn Mohr, Melissa Johnson, Travis Cooper, et al.
International Journal of Antimicrobial Agents|February 12, 2013
Safety of daptomycin in patients completing more than 14 days of therapy: results from the Cubicin® Outcomes Registry and experienceShruta Rege, John Mohr, Kenneth C Lamp, et al.
Emerging Infectious Diseases|June 21, 2005
Community-associated methicillin-resistant Staphylococcus aureus in pediatric patientsTheresa J Ochoa, John Mohr, Audrey Wanger, et al.
BMC Infectious Diseases|March 1, 2017
Effect of prior receipt of antibiotics on the pathogen distribution and antibiotic resistance profile of key Gram-negative pathogens among patients with hospital-onset urinary tract infectionsMonique R Bidell, Melissa Palchak Opraseuth, Min Yoon, et al.
Journal of Clinical Microbiology|March 31, 2012
Correlation of clinical outcomes with β-glucan levels in patients with invasive candidiasisCharles R Sims, Siraya Jaijakul, John Mohr, et al.
Pageof 1